aOne subject concealed the history of epilepsy and taking magnesium valproate for a long time.
Table 2 Summary of the key pharmacokinetic (PK) parameters of SHR2554.
Cmax, maximum plasma concentration; Tmax, time to Cmax, AUC0-t, area under the concentration-time to the last quantifiable concentration; AUC0-∞, area under the concentration-time to infinity; t1/2, elimination half-life; CL/F, apparent clearance; VZ/F, apparent volume of distribution
aPK parameters are presented as geometric mean (geometric coefficient of variation), with the exception of Tmax, which is presented as median (range)
bIn the SHR2554 administration alone phase the AUC0-∞of 1 subject could not be accurately calculated due to AUCt-∞ >20%, so the number of subjects was 16.
cIn the SHR2554 coadministration with rifampin phase the AUC0-∞ of 2 subjects could not be accurately calculated due to AUCt-∞ >20%, so the number of subjects was 15.